Heron Therapeutics, Inc. (LON:0J4V)
1.140
-0.060 (-4.97%)
Feb 12, 2026, 3:01 PM GMT
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $38.21M USD in the quarter ending September 30, 2025, with 16.47% growth. This brings the company's revenue in the last twelve months to $155.10M, up 12.60% year-over-year. In the year 2024, Heron Therapeutics had annual revenue of $144.29M with 13.57% growth.
Revenue (ttm)
$155.10M
Revenue Growth
+12.60%
P/S Ratio
1.34
Revenue / Employee
$1.27M
Employees
122
Market Cap
154.80M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 144.29M | 17.24M | 13.57% |
| Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
| Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
| Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
| Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
| Dec 31, 2019 | 145.97M | 68.49M | 88.41% |
| Dec 31, 2018 | 77.47M | 46.71M | 151.81% |
| Dec 31, 2017 | 30.77M | 29.49M | 2,305.55% |
| Dec 31, 2016 | 1.28M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 646.00K | -655.00K | -50.35% |
| Dec 31, 2010 | 1.30M | 40.00K | 3.17% |
| Dec 31, 2009 | 1.26M | 892.00K | 241.73% |
| Dec 31, 2008 | 369.00K | -43.00K | -10.44% |
| Dec 31, 2007 | 412.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | 5.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Optima Health | 113.75M |
| Animalcare Group | 81.07M |
| Tristel | 46.46M |
| Diaceutics | 34.40M |
Heron Therapeutics News
- 21 days ago - FINANCIAL CONSULATE, INC Sells 500 Shares of Heron Therapeutics Inc (HRTX) - GuruFocus
- 4 weeks ago - Heron Therapeutics (HRTX) Surpasses Q4 Revenue Expectations - GuruFocus
- 4 weeks ago - HRTX Reports Strong Q4 2025 Revenue Growth Driven by Acute Care Products - GuruFocus
- 4 weeks ago - Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth - GlobeNewsWire
- 2 months ago - Heron Therapeutics (HRTX) Gains Recognition for APONVIE in PONV Management - GuruFocus
- 2 months ago - Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) - GlobeNewsWire
- 3 months ago - Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear - Seeking Alpha
- 3 months ago - Heron Therapeutics Inc (HRTX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - GuruFocus